Company intelligence / Profile preview

iNtRON Biotechnology

Sungnam-si, Gyeonggi-do, SOUTH KOREAintronbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

iNtRON has several clinical-stage programs targeting bacterial infections with engineered endolysins and small molecules. Its lead assets include SML-200 and NFA-014 for streptococcal/Gram-negative infections. The company has outlicensed SAL200 to Roivant Sciences for further development. Diagnostic kits are already commercialized globally.

Therapeutic areas: ImmunologyNeurologyInfectious Diseases
Modalities: Bacteriophage therapyEndolysin-based biologicsSmall molecule drugsBiological products
Industry: Biotech

Drug pipeline

17 assets

tonabacase

16 more assets in the full pipeline.

Request access →

Partnerships

Roivant Sciences (SAL200 rights/license)various overseas distributors of diagnostics kits

Beyond the preview

Go deeper on iNtRON Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iNtRON Biotechnology.

Explore the full profile